89bio ETNB Stock
14.84 USD
{{ price }}
0.000000%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
Tech Market Middle
Market Cap
2.2B USD
LOW - HIGH [24H]
14.82
-
14.87 USD
VOLUME [24H]
39.23M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-3.69 USD
89bio Price Chart
89bio ETNB Financial and Trading Overview
| 89bio stock price | 14.84 USD |
| Previous Close | 9.48 USD |
| Open | 9.49 USD |
| Bid | 8.97 USD x 100 |
| Ask | 9.06 USD x 100 |
| Day's Range | 8.79 - 9.49 USD |
| 52 Week Range | 4.16 - 11.84 USD |
| Volume | 1.74M USD |
| Avg. Volume | 1.9M USD |
| Market Cap | 1.32B USD |
| Beta (5Y Monthly) | 1.357 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.69 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.36 USD |
ETNB Valuation Measures
| Enterprise Value | 715.58M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.1428573 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.1750665 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.775 |
Trading Information
89bio Stock Price History
| Beta (5Y Monthly) | 1.357 |
| 52-Week Change | 15.64% |
| S&P500 52-Week Change | 18.63% |
| 52 Week High | 11.84 USD |
| 52 Week Low | 4.16 USD |
| 50-Day Moving Average | 9.99 USD |
| 200-Day Moving Average | 8.68 USD |
ETNB Share Statistics
| Avg. Volume (3 month) | 1.9M USD |
| Avg. Daily Volume (10-Days) | 1.59M USD |
| Shares Outstanding | 145.98M |
| Float | 101.47M |
| Short Ratio | 8.85 |
| % Held by Insiders | 0.54% |
| % Held by Institutions | 111.62% |
| Shares Short | 15.46M |
| Short % of Float | 14.73% |
| Short % of Shares Outstanding | 10.59% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -39.93% |
| Return on Equity (ttm) | -69.29% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -403248992 USD |
| Net Income Avi to Common (ttm) | -386672992 USD |
| Diluted EPS (ttm) | -3.46 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 638.78M USD |
| Total Cash Per Share (mrq) | 4.38 USD |
| Total Debt (mrq) | 37.58M USD |
| Total Debt/Equity (mrq) | 6.21 USD |
| Current Ratio (mrq) | 18.027 |
| Book Value Per Share (mrq) | 4.147 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -399840000 USD |
| Levered Free Cash Flow (ttm) | -261869744 USD |
Profile of 89bio
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 655 Montgomery Street |
| ZIP | 94111 |
| Phone | 415 432 9270 |
| Website | https://www.89bio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 93 |
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Q&A For 89bio Stock
What is a current ETNB stock price?
89bio ETNB stock price today per share is 14.84 USD.
How to purchase 89bio stock?
You can buy ETNB shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for 89bio?
The stock symbol or ticker of 89bio is ETNB.
Which industry does the 89bio company belong to?
The 89bio industry is Biotechnology.
How many shares does 89bio have in circulation?
The max supply of 89bio shares is 148.49M.
What is 89bio Price to Earnings Ratio (PE Ratio)?
89bio PE Ratio is now.
What was 89bio earnings per share over the trailing 12 months (TTM)?
89bio EPS is -3.69 USD over the trailing 12 months.
Which sector does the 89bio company belong to?
The 89bio sector is Healthcare.
89bio ETNB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2309.83 USD — |
+1.58
|
— — | 2282.44 USD — | 2312.75 USD — | — - | — — |
| US Tech Biotechnology NBI | 5366.46 USD — |
+1.2
|
— — | 5276.16 USD — | 5372.71 USD — | — - | — — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
- {{ link.label }} {{link}}